ATE429252T1 - Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen - Google Patents
Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden genInfo
- Publication number
- ATE429252T1 ATE429252T1 AT05797742T AT05797742T ATE429252T1 AT E429252 T1 ATE429252 T1 AT E429252T1 AT 05797742 T AT05797742 T AT 05797742T AT 05797742 T AT05797742 T AT 05797742T AT E429252 T1 ATE429252 T1 AT E429252T1
- Authority
- AT
- Austria
- Prior art keywords
- adeno
- sequence
- associated viral
- gene encoding
- viral vector
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000013603 viral vector Substances 0.000 title 1
- 102000039471 Small Nuclear RNA Human genes 0.000 abstract 3
- 108020004688 Small Nuclear RNA Proteins 0.000 abstract 3
- 239000013607 AAV vector Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0451861A FR2874384B1 (fr) | 2004-08-17 | 2004-08-17 | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
| PCT/FR2005/050642 WO2006021724A2 (fr) | 2004-08-17 | 2005-08-02 | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429252T1 true ATE429252T1 (de) | 2009-05-15 |
Family
ID=34948645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05797742T ATE429252T1 (de) | 2004-08-17 | 2005-08-02 | Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20120077860A1 (de) |
| EP (2) | EP1778297B1 (de) |
| JP (1) | JP4885136B2 (de) |
| AT (1) | ATE429252T1 (de) |
| CA (1) | CA2576462C (de) |
| DE (1) | DE602005014114D1 (de) |
| DK (1) | DK1778297T3 (de) |
| ES (1) | ES2324948T3 (de) |
| FR (1) | FR2874384B1 (de) |
| PL (1) | PL1778297T3 (de) |
| PT (1) | PT1778297E (de) |
| WO (1) | WO2006021724A2 (de) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2206781T1 (sl) | 2004-06-28 | 2016-05-31 | The University Of Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe |
| EP2152873A2 (de) * | 2007-03-16 | 2010-02-17 | Biorigen S.r.l | Technologie zur regulierung der genexpression und nichtkodierende rna für diagnose und therapie |
| EP2762567B1 (de) | 2008-10-24 | 2016-07-13 | Sarepta Therapeutics, Inc. | Mehrere Exon-Skipping-Zusammensetzungen für DMD |
| EP2396343B1 (de) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung |
| CN102625840A (zh) * | 2009-04-10 | 2012-08-01 | 肌肉学研究协会 | 用于治疗疾病的三环dna反义寡核苷酸、组合物和方法 |
| SMT201800579T1 (it) | 2009-11-12 | 2019-01-11 | Univ Western Australia | Molecole antisenso e metodi per trattare patologie |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| JP5894543B2 (ja) * | 2010-03-17 | 2016-03-30 | アソシアシオン インスティテュト ドゥ ミョロジー | 神経筋疾患の治療のための修飾型Ｕ７ｓｎＲＮＡ |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| JP6042825B2 (ja) | 2011-02-10 | 2016-12-14 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法 |
| EP2500434A1 (de) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsidfreie AAV-Vektoren, Zusammensetzungen und Verfahren zur Vektorherstellung und Genlieferung |
| WO2012136811A1 (en) | 2011-04-06 | 2012-10-11 | Universite Pierre Et Marie Curie (Paris 6) | A skeletal muscle-specific enhancer |
| US9987354B2 (en) | 2011-04-29 | 2018-06-05 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells |
| EP2900686B1 (de) | 2012-09-28 | 2020-06-10 | The University of North Carolina At Chapel Hill | Gegen oligodendrozyten gerichtete aav-vektoren |
| AU2014236140B2 (en) | 2013-03-14 | 2019-10-03 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| NZ732507A (en) | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| WO2014143932A1 (en) | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Synthetic adeno-associated virus inverted terminal repeats |
| CN105163764B (zh) | 2013-03-15 | 2019-11-12 | 北卡罗来纳-查佩尔山大学 | 双重聚糖结合aav载体的方法和组合物 |
| EP2986632B1 (de) | 2013-04-20 | 2018-09-05 | Research Institute at Nationwide Children's Hospital | Freisetzung von rekombinantem adeno-assoziiertem virus von exon-2-gerichteten u7snrna-polynukleotidkonstrukten |
| CN110251675A (zh) | 2013-05-03 | 2019-09-20 | 西莱克塔生物科技公司 | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 |
| ES2739850T3 (es) | 2013-09-11 | 2020-02-04 | Synthena Ag | Acidos nucleicos y procedimientos para el tratamiento de la enfermedad de Pompe |
| CN106661580B (zh) | 2014-06-10 | 2022-02-15 | 鹿特丹伊拉斯谟大学医疗中心 | 用于治疗庞帕病的反义寡核苷酸 |
| CA2955285C (en) | 2014-07-31 | 2023-09-26 | Association Institut De Myologie | Treatment of amyotrophic lateral sclerosis |
| JP6986444B2 (ja) | 2014-08-09 | 2021-12-22 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｄｍｄ遺伝子のエクソン５内の内部リボソーム進入部位を活性化するための方法及び材料 |
| WO2016037161A2 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| BR112017010447A2 (pt) | 2014-11-21 | 2018-05-15 | The University Of North Carolina At Chapel Hill | vetores de aav direcionados ao sistema nervoso central |
| US10907176B2 (en) | 2015-01-14 | 2021-02-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| EP3258961A4 (de) | 2015-02-20 | 2018-08-22 | Board of Regents, The University of Texas System | Verfahren und zusammensetzungen für abgeschwächte chlamydien als impfstoff und vektor |
| EP3353301A1 (de) | 2015-09-21 | 2018-08-01 | Association Institut de Myologie | Antisense-oligonukleotide und verwendungen davon |
| JP7064214B2 (ja) | 2015-09-28 | 2022-05-10 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 抗体回避性ウイルスベクターのための方法および組成物 |
| FR3044926B1 (fr) * | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
| CN108602859B (zh) | 2015-12-14 | 2023-05-26 | 北卡罗来纳大学教堂山分校 | 增强细小病毒载体递送的修饰衣壳蛋白 |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| SG10202107429WA (en) | 2017-01-06 | 2021-08-30 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| ES2966692T3 (es) | 2017-03-15 | 2024-04-23 | Univ North Carolina Chapel Hill | Vectores de virus adenoasociados poliploides y métodos de fabricación y uso de los mismos |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| EP3759218A4 (de) | 2018-02-28 | 2021-12-08 | The University of North Carolina at Chapel Hill | Verfahren und zusammensetzungen für antikörperausweichende virusvektoren |
| MX2020010464A (es) | 2018-04-03 | 2021-01-29 | Vectores de virus que evitan anticuerpos. | |
| US12091435B2 (en) | 2018-04-03 | 2024-09-17 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| JP7425738B2 (ja) | 2018-04-03 | 2024-01-31 | ギンコ バイオワークス インコーポレイテッド | 眼組織を標的とするウイルスベクター |
| AU2019287468B2 (en) | 2018-06-12 | 2024-10-10 | The University Of North Carolina At Chapel Hill | Synthetic liver-tropic adeno-associated virus capsids and uses thereof |
| EP3806868A4 (de) * | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | Exon-skipping-oligomere für muskeldystrophie |
| AU2019290228A1 (en) | 2018-06-22 | 2021-01-28 | AskBio Inc. | Vectors for gene delivery that persist within cells |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2019316103B2 (en) | 2018-08-02 | 2026-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2020041634A1 (en) * | 2018-08-22 | 2020-02-27 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inhibiting expression of dystrophia myotonica protein kinase and/or interfering with a trinucleotide repeat expansion in the 3' untranslated region of the dmpk gene |
| JP7698583B2 (ja) | 2019-03-21 | 2025-06-25 | ギンコ バイオワークス インコーポレイテッド | 組換えアデノ随伴ウイルスベクター |
| CN113767110A (zh) | 2019-04-26 | 2021-12-07 | 北卡罗来纳-查佩尔山大学 | 用于双重聚糖结合aav2.5载体的方法和组合物 |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| KR102452590B1 (ko) * | 2019-08-01 | 2022-10-12 | 기초과학연구원 | CRISPR/Cas9 매개 체세포 핵 이식에 의한 개 디스트로핀병증 모델 생성 및 이의 용도 |
| IL292297A (en) | 2019-10-17 | 2022-06-01 | Stridebio Inc | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| EP4054618A1 (de) | 2019-11-06 | 2022-09-14 | Association Institut de Myologie | Kombinationstherapie bei muskelerkrankungen |
| CA3171436A1 (en) | 2020-04-09 | 2021-10-14 | Association Institut De Myologie | Antisense sequences for treating amyotrophic lateral sclerosis |
| WO2021226008A1 (en) | 2020-05-05 | 2021-11-11 | The University Of North Carolina At Chapel Hill | Modified adeno-associated virus 5 capsids and uses thereof |
| WO2022026516A1 (en) * | 2020-07-29 | 2022-02-03 | The Board Of Regents Of The University Of Texas System | Transgene cassettes, aav vectors, and aav viral vectors for expression of human codon-optimized cstb |
| CA3189878A1 (en) | 2020-08-19 | 2022-02-24 | Colin O'BANION | Adeno-associated virus vectors for treatment of rett syndrome |
| EP4214317A2 (de) | 2020-09-15 | 2023-07-26 | Research Institute at Nationwide Children's Hospital | Aav-vermittelte homologieunabhängige gezielte integrationsgeneditierung zur korrektur verschiedener dmd-mutationen bei patienten mit muskeldystrophie |
| WO2022093769A1 (en) | 2020-10-28 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav2.5 vector |
| CN116490514A (zh) | 2020-10-28 | 2023-07-25 | 北卡罗来纳-查佩尔山大学 | 用于双重聚糖结合aav2.5载体的方法和组合物 |
| TW202242124A (zh) | 2021-01-14 | 2022-11-01 | 美商史崔德生物公司 | 靶向ｔ細胞之ａａｖ載體 |
| AU2022208480A1 (en) | 2021-01-15 | 2023-08-17 | Outpace Bio, Inc. | Small molecule-regulated gene expression system |
| EP4301462A1 (de) | 2021-03-04 | 2024-01-10 | Research Institute at Nationwide Children's Hospital | Produkte und verfahren zur behandlung von dystrophinbasierten myopathien mit crispr-cas9 zur korrektur von dmd-exon-duplikationen |
| EP4323015A4 (de) | 2021-04-16 | 2025-10-22 | Askbio Inc | Rationale polyploide aav-virionen, die die blut-hirn-schranke durchqueren und eine reduzierte humorale antwort hervorrufen |
| EP4326752A1 (de) | 2021-04-23 | 2024-02-28 | Research Institute at Nationwide Children's Hospital | Produkte und verfahren zur behandlung von muskeldystrophie |
| US11771776B2 (en) * | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| EP4119682A1 (de) | 2021-07-13 | 2023-01-18 | Genethon | Verfahren zur bestimmung der natur von dna-verunreinigungen in viruspartikeln |
| KR20240052034A (ko) | 2021-09-03 | 2024-04-22 | 태시트 테라퓨틱스, 인코포레이티드 | 스플라이세오솜 구성요소의 동원을 통한 rna 편집 |
| EP4215614A1 (de) | 2022-01-24 | 2023-07-26 | Dynacure | Kombinationstherapie für dystrophin-verwandte krankheiten |
| WO2023150687A1 (en) | 2022-02-04 | 2023-08-10 | Ginkgo Bioworks, Inc. | Recombinant adeno-associated virus vectors, and methods of use thereof |
| CN119137273A (zh) | 2022-03-04 | 2024-12-13 | 洛卡纳生物股份有限公司 | 包括工程化核内小RNA（snRNA）的组合物和方法 |
| CN120129747A (zh) * | 2022-10-11 | 2025-06-10 | 广州瑞风生物科技有限公司 | snRNA核酸分子及其应用 |
| WO2024124019A2 (en) | 2022-12-07 | 2024-06-13 | Ginkgo Bioworks, Inc. | Aav vectors targeting hematopoietic stem cells |
| WO2025079025A1 (en) | 2023-10-13 | 2025-04-17 | Takeda Pharmaceutical Company Limited | Ides-rapamycin conjugate in aav gene therapy |
| WO2025179121A1 (en) | 2024-02-21 | 2025-08-28 | Research Institute At Nationwide Children's Hospital | Exon 17-targeted nucleic acids, compositions, and methods for treatment of dystrophin-based myopathies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000325085A (ja) | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | デュシェンヌ型筋ジストロフィー治療剤 |
| ATE403715T1 (de) * | 1999-08-09 | 2008-08-15 | Targeted Genetics Corp | Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| US7638120B2 (en) * | 2000-03-14 | 2009-12-29 | Thomas Jefferson University | High transgene expression of a pseudotyped adeno-associated virus type |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| EP1191097A1 (de) * | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induktion von "exon-skipping" in eukaryotischen Zellen |
| JP2005512598A (ja) * | 2001-12-21 | 2005-05-12 | オックスフォード バイオメディカ （ユーケー） リミテッド | Ｅｉａｖなどのレンチウイルス発現ベクターを使用するトランスジェニック生物の作製方法 |
| ITRM20020253A1 (it) | 2002-05-08 | 2003-11-10 | Univ Roma | Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. |
| AU2003225410A1 (en) * | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
-
2004
- 2004-08-17 FR FR0451861A patent/FR2874384B1/fr not_active Expired - Lifetime
-
2005
- 2005-08-02 PT PT05797742T patent/PT1778297E/pt unknown
- 2005-08-02 AT AT05797742T patent/ATE429252T1/de active
- 2005-08-02 JP JP2007526520A patent/JP4885136B2/ja not_active Expired - Fee Related
- 2005-08-02 CA CA2576462A patent/CA2576462C/fr not_active Expired - Lifetime
- 2005-08-02 DE DE602005014114T patent/DE602005014114D1/de not_active Expired - Lifetime
- 2005-08-02 ES ES05797742T patent/ES2324948T3/es not_active Expired - Lifetime
- 2005-08-02 US US11/573,811 patent/US20120077860A1/en not_active Abandoned
- 2005-08-02 EP EP05797742A patent/EP1778297B1/de not_active Expired - Lifetime
- 2005-08-02 EP EP08163844A patent/EP2014309A1/de not_active Withdrawn
- 2005-08-02 PL PL05797742T patent/PL1778297T3/pl unknown
- 2005-08-02 WO PCT/FR2005/050642 patent/WO2006021724A2/fr not_active Ceased
- 2005-08-02 DK DK05797742T patent/DK1778297T3/da active
-
2012
- 2012-04-27 US US13/458,037 patent/US20130072541A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1778297B1 (de) | 2009-04-22 |
| CA2576462C (fr) | 2013-03-12 |
| FR2874384B1 (fr) | 2010-07-30 |
| PT1778297E (pt) | 2009-07-23 |
| PL1778297T3 (pl) | 2009-10-30 |
| DK1778297T3 (da) | 2009-07-27 |
| CA2576462A1 (fr) | 2006-03-02 |
| WO2006021724A2 (fr) | 2006-03-02 |
| JP2008509695A (ja) | 2008-04-03 |
| EP2014309A1 (de) | 2009-01-14 |
| EP1778297A2 (de) | 2007-05-02 |
| DE602005014114D1 (de) | 2009-06-04 |
| FR2874384A1 (fr) | 2006-02-24 |
| JP4885136B2 (ja) | 2012-02-29 |
| WO2006021724A3 (fr) | 2006-08-31 |
| ES2324948T3 (es) | 2009-08-20 |
| US20120077860A1 (en) | 2012-03-29 |
| US20130072541A1 (en) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE429252T1 (de) | Adeno-assoziierter viraler vektor zur exon- überspringung in einem für ein protein mit überflüssiger domäne kodierenden gen | |
| GEP20125594B (en) | Sclerostin binding agents | |
| BR112012008054A2 (pt) | domínios catalíticos de lisil oxidase e loxl2 | |
| DE60318391D1 (de) | Bakteriophagen-lysin | |
| DE602004027538D1 (de) | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon | |
| CY1116649T1 (el) | Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα | |
| ATE540115T1 (de) | Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands | |
| EP1859046A4 (de) | Expressionsvektor für tierische zelle mit wenigstens einer kopie von mar-dna-sequenzen am 3'-ende des transkriptionsterminationsbereichs eines gens sowie verfahren zur expression eines fremdgens unter verwendung des vektors | |
| DE50110597D1 (de) | L-Aminosäure-Oxidase aus Rhodococcus-Arten | |
| DK0811071T3 (da) | Amplifikeringssekvenser hidrørende fra desmin-genet, vektorer indeholdende disse sekvenser og anvendelse heraf til fremstilling af proteiner | |
| ATE529441T1 (de) | Expression von proteinen in e.coli | |
| WO2003020887A3 (en) | Gene identification | |
| WO2002066636A3 (en) | T cell receptor variants expressed in mesenchymal cells and uses thereof | |
| AR049224A1 (es) | Composiciones y metodos para la modificacion de la expresion genica | |
| ATE428783T1 (de) | Expressionssystem für sirna | |
| PE20000177A1 (es) | GEN dtsR TERMOSENSIBLE | |
| DK1625152T3 (da) | Peptider, som modulerer sktiviteten af Engrailed-transskriptionsfaktoren | |
| EP1842911A4 (de) | Hla bindende peptide, für diese codierende dna-fragmente und rekombinante vektoren | |
| DE502005007057D1 (de) | Verfahren zur herstellung von (s)-butan-2-ol | |
| EP1801211A4 (de) | Hla bindendes peptid, dieses codierendes dna-fragment und rekombinanter vektor | |
| DK1725580T3 (da) | Isosterisk transformation | |
| EP1757687A4 (de) | Hla bindendes peptid, dessen vorstufe, dafür codierendes dna-fragment und rekombinanter vektor | |
| ES2271040T3 (es) | Factores especificos de hifa procedentes de candida albicans. | |
| DK1196440T3 (da) | Terapeutiske peptider afledt af subsekvenser af BPI | |
| Jones | Landmark implications? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1778297 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |